Organon & Co (OGN) - Total Assets
Based on the latest financial reports, Organon & Co (OGN) holds total assets worth $13.00 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Organon & Co (OGN) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Organon & Co - Total Assets Trend (2018–2025)
This chart illustrates how Organon & Co's total assets have evolved over time, based on quarterly financial data. See OGN total equity for net asset value and shareholders' equity analysis.
Organon & Co - Asset Composition Analysis
Current Asset Composition (December 2025)
Organon & Co's total assets of $13.00 Billion consist of 33.8% current assets and 66.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $574.00 Million | 4.5% |
| Accounts Receivable | $1.43 Billion | 11.1% |
| Inventory | $1.41 Billion | 10.9% |
| Property, Plant & Equipment | $1.46 Billion | 11.3% |
| Intangible Assets | $1.13 Billion | 8.8% |
| Goodwill | $4.15 Billion | 32.3% |
Asset Composition Trend (2018–2025)
This chart illustrates how Organon & Co's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Organon & Co (OGN) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Organon & Co's current assets represent 33.8% of total assets in 2025, a decrease from 35.4% in 2018.
- Cash Position: Cash and equivalents constituted 4.5% of total assets in 2025, up from 2.3% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 40.0% of total assets, a decrease from 50.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 32.3% of total assets.
Organon & Co Competitors by Total Assets
Key competitors of Organon & Co based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biogen Inc
NASDAQ:BIIB
|
USA | $29.44 Billion |
|
Virbac SA
PA:VIRP
|
France | €1.82 Billion |
|
Aurora Optoelectronics Co Ltd
SHG:600666
|
China | CN¥2.22 Billion |
|
NanJing Pharmaceutical Co Ltd
SHG:600713
|
China | CN¥34.05 Billion |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
|
Brazil | R$3.66 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$2.28 Million |
|
Eli Lilly and Company
SA:LILY34
|
Brazil | R$112.48 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$207.62 Billion |
Organon & Co - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.97 | 1.67 | 1.31 |
| Quick Ratio | 1.42 | 1.15 | 1.01 |
| Cash Ratio | 0.00 | 0.21 | 0.25 |
| Working Capital | $2.43 Billion | $1.76 Billion | $936.00 Million |
Organon & Co - Advanced Valuation Insights
This section examines the relationship between Organon & Co's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.90 |
| Latest Market Cap to Assets Ratio | 0.27 |
| Asset Growth Rate (YoY) | -1.8% |
| Total Assets | $12.87 Billion |
| Market Capitalization | $3.52 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Organon & Co's assets below their book value (0.27x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Organon & Co's assets decreased by 1.8% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Organon & Co (2018–2025)
The table below shows the annual total assets of Organon & Co from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $12.87 Billion | -1.79% |
| 2024-12-31 | $13.10 Billion | +8.65% |
| 2023-12-31 | $12.06 Billion | +10.07% |
| 2022-12-31 | $10.96 Billion | +2.57% |
| 2021-12-31 | $10.68 Billion | +5.66% |
| 2020-12-31 | $10.11 Billion | -4.16% |
| 2019-12-31 | $10.55 Billion | +0.51% |
| 2018-12-31 | $10.49 Billion | -- |
About Organon & Co
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive… Read more